Science Explorer Back to mapMap
Discussion
Company · Tübingen · Germany

Immatics Biotechnologies (Germany)

immatics.comROR OpenAlex
Research works
57
◆ 1% vs 2018-21
Citations
2.5k
44.1 per fractional work
Top-10% rate
24.7%
all institutions 10.0%
Open access
51%
world 40%
International
40%
world 18%
Immatics Biotechnologies (Germany)

Not ranked overall: Immatics Biotechnologies (Germany) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Immatics Biotechnologies (Germany) work in?

In all years, 49% of research at Immatics Biotechnologies (Germany) is in Life Sciences, 45% in Health Sciences. Its largest fields are Medicine (45%), Immunology and Microbiology (27%), Biochemistry, Genetics and Molecular Biology (20%). It does 2.6× the world's share of Life Sciences.

Life Sciences: 28 fractional works · 48.6% of its workImmunology and Microbiology: 15 fractional works · 27.3% of its workImmunology: 15 fractional works · 27.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workBiochemistry, Genetics and Molecular Biology: 11 fractional works · 20.0% of its workMolecular Biology: 9 fractional works · 16.5% of its workGenetics: 1 fractional works · 1.1% of its workCancer Research: 0 fractional works · 0.8% of its workBiotechnology: 0 fractional works · 0.6% of its workCell Biology: 0 fractional works · 0.4% of its workBiochemistry: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.3% of its workAgricultural and Biological Sciences: 0 fractional works · 0.6% of its workPlant Science: 0 fractional works · 0.6% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 0.5% of its workPharmaceutical Science: 0 fractional works · 0.5% of its workNeuroscience: 0 fractional works · 0.2% of its workHealth Sciences: 26 fractional works · 45.2% of its workMedicine: 26 fractional works · 45.2% of its workOncology: 15 fractional works · 26.2% of its workRadiology, Nuclear Medicine and Imaging: 5 fractional works · 9.6% of its workGenetics: 1 fractional works · 2.1% of its workPulmonary and Respiratory Medicine: 1 fractional works · 1.4% of its workHematology: 1 fractional works · 1.2% of its workPhysiology: 0 fractional works · 0.9% of its workPathology and Forensic Medicine: 0 fractional works · 0.8% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 0.6% of its workInfectious Diseases: 0 fractional works · 0.5% of its workSurgery: 0 fractional works · 0.5% of its workEpidemiology: 0 fractional works · 0.4% of its workNephrology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.7% of its workPhysical Sciences: 3 fractional works · 5.2% of its workEnvironmental Science: 2 fractional works · 3.1% of its workNature and Landscape Conservation: 1 fractional works · 1.9% of its workEnvironmental Engineering: 0 fractional works · 0.6% of its workGlobal and Planetary Change: 0 fractional works · 0.3% of its workEcology: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workEngineering: 1 fractional works · 1.1% of its workBuilding and Construction: 0 fractional works · 0.6% of its workBiomedical Engineering: 0 fractional works · 0.5% of its workChemistry: 0 fractional works · 0.8% of its workOrganic Chemistry: 0 fractional works · 0.5% of its workPhysical and Theoretical Chemistry: 0 fractional works · 0.3% of its workMaterials Science: 0 fractional works · 0.1% of its workSocial Sciences: 1 fractional works · 1.0% of its workSocial Sciences: 0 fractional works · 0.7% of its workSociology and Political Science: 0 fractional works · 0.4% of its workHealth: 0 fractional works · 0.3% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.3% of its workEconomics and Econometrics: 0 fractional works · 0.3% of its workALL ITS WORKImmaticsBiotechnologies…57fractional works, all years
Life Sciences49%Physical Sciences5%Health Sciences45%Social Sciences1%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 12 fields, with their numbers
    1. Immunology and Microbiology1527.3%
    2. Biochemistry, Genetics and Molecular Biology1120.0%
    3. Agricultural and Biological Sciences00.6%
    4. Pharmacology, Toxicology and Pharmaceutics00.5%
    5. Neuroscience00.2%
    1. Medicine2645.2%
    1. Environmental Science23.1%
    2. Engineering11.1%
    3. Chemistry00.8%
    4. Materials Science00.1%
    1. Social Sciences00.7%
    2. Economics, Econometrics and Finance00.3%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 2.32× its world share, 2 worksBiochemistry, Geneti…Immunology and Microbiology: 25.10× its world share, 4 worksImmunology and Micro…Neuroscience: 0.24× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 5.52× its world share, 0 worksPharmacology, Toxico…Chemistry: 1.24× its world share, 0 worksChemistryEngineering: 0.04× its world share, 0 worksEngineeringMaterials Science: 0.13× its world share, 0 worksMaterials ScienceMedicine: 2.97× its world share, 8 worksMedicine1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 25.1×. Every wedge is a field page.

All 8 fields, with their numbers
  1. Immunology and Microbiology25.10×4 works
  2. Pharmacology, Toxicology and Pharmaceutics5.52×0 works
  3. Medicine2.97×8 works
  4. Biochemistry, Genetics and Molecular Biology2.32×2 works
  5. Chemistry1.24×0 works
  6. Neuroscience0.24×0 works
  7. Materials Science0.13×0 works
  8. Engineering0.04×0 works

Who are the top researchers at Immatics Biotechnologies (Germany)?

Ranked on the quality score, Jens Fritsche, Harpreet Singh‐Jasuja and Norbert Hilf lead among researchers whose main affiliation is Immatics Biotechnologies (Germany).

  1. 1 Jens Fritsche Germany · #134,126 worldwide 5.4k citations · 142 works
  2. 2 Harpreet Singh‐Jasuja Germany · #187,305 worldwide 6.3k citations · 54 works
  3. 3 Norbert Hilf Germany · #202,990 worldwide 4.6k citations · 167 works
  4. 4 Toni Weinschenk Germany · #222,749 worldwide 6.7k citations · 197 works
  5. 5 Steffen Walter Germany · #296,374 worldwide 6.3k citations · 253 works
  6. 6 Regina Mendrzyk Germany · #612,150 worldwide 2.1k citations · 123 works
  7. 7 Mamta Kalra Germany · #614,120 worldwide 2k citations · 41 works
  8. 8 Claudia Simone Wagner Germany · #715,068 worldwide 2.6k citations · 138 works
  9. 9 Carsten Reinhardt Germany · #818,094 worldwide 5.2k citations · 169 works
  10. 10 Dominik Maurer Germany · #827,708 worldwide 3k citations · 185 works
All ranked researchers at Immatics Biotechnologies (Germany)

What are the most cited papers from Immatics Biotechnologies (Germany)?

The most cited paper from Immatics Biotechnologies (Germany) is "Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing" (Mahesh Chandra Yadav, Suchit Jhunjhunwala, Qui T. Phung et al., 2014), with 1,217 citations. Next come "Actively personalized vaccination trial for newly diagnosed glioblastoma" (954) and "Cancer classification using the Immunoscore: a worldwide task force" (807).

Most cited papers
#PaperReleasedCitations
1 Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing Mahesh Chandra Yadav, Suchit Jhunjhunwala, Qui T. Phung et al. · Nature 25 Nov 2014 1,217
2 Actively personalized vaccination trial for newly diagnosed glioblastoma Norbert Hilf et al. · Nature 19 Dec 2018 954
3 Cancer classification using the Immunoscore: a worldwide task force Jérôme Galon et al. · Journal of Translational Medicine Open access 3 Oct 2012 807
4 Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival Steffen Walter et al. · Nature Medicine 29 Jul 2012 793
5 SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition Annika Nelde et al. · Nature Immunology Open access 30 Sep 2020 647
All 59 most cited papers, with filters and sorting

Which keywords describe research at Immatics Biotechnologies (Germany)?

By fractional works in all years, weighted toward what it does more of than the world: Cancer Immunotherapy, Antigen Presentation, Immunotherapy, Innate Immunity, Immunity, Lymphoma, Tumor Regression and Dendritic Cells.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Cancer Immunotherapy18▲ 230×2 topics
  2. Antigen Presentation14▲ 241×2 topics
  3. Immunotherapy10▲ 27×8 topics
  4. Innate Immunity10▲ 49×5 topics
  5. Immunity10▲ 50×4 topics
  6. Lymphoma10▲ 113×2 topics
  7. Tumor Regression9▲ 189×2 topics
  8. Dendritic Cells9▲ 141×1 topic
  9. Tumor Antigen9▲ 199×1 topic
  10. CAR T Cells9▲ 369×1 topic
  11. Chimeric Antigen Receptor9▲ 369×1 topic
  12. Monoclonal Antibodies6▲ 80×2 topics
  13. Glycosylation6▲ 50×3 topics
  14. Tumor Microenvironment5▲ 27×5 topics
  15. Fc Receptors5▲ 93×1 topic
  16. Therapeutic Antibodies5▲ 72×1 topic
  17. Epitope Prediction4▲ 424×1 topic
  18. Peptide-MHC Binding4▲ 424×1 topic
  19. Immune Checkpoint Blockade4▲ 132×1 topic
  20. PD-1 and PD-L14▲ 132×1 topic
  21. NK Cell Recognition2▲ 42×1 topic
  22. Natural Killer Cells2▲ 42×1 topic
  23. PET Imaging2▲ 15×4 topics
  24. Cancer Therapy2▲ 4.6×7 topics
  25. Autoimmunity2▲ 13×2 topics
  26. Foxp32▲ 36×1 topic
  27. Prognostic Factors2▲ 5.7×7 topics
  28. TGF-ß2▲ 15×1 topic
  29. Angiogenesis1▲ 5.8×4 topics
  30. Biopharmaceuticals1▲ 33×2 topics
  31. Gene Therapy1▲ 8.4×4 topics
  32. Biosimilars1▲ 146×1 topic
  33. Immunogenicity1▲ 43×1 topic
  34. Immunosuppression1▲ 18×2 topics
  35. Stromal Cells1▲ 23×2 topics
  36. Fibroblast Activation Protein1▲ 37×1 topic
  37. N-terminal Acetylation1▲ 37×1 topic
  38. Rituximab1▲ 12×2 topics
  39. Biosphere Reserves1▲ 154×1 topic
  40. Therapeutic Targets1▲ 7.8×3 topics

Which research topics does Immatics Biotechnologies (Germany) publish most on?

By volume in 2022-now: CAR-T cell therapy research, Monoclonal and Polyclonal Antibodies Research, Immune Cell Function and Interaction and Immunotherapy and Immune Responses.

CAR-T cell therapy resea…4CAR-T cell therapy research: 4 fractional worksMonoclonal and Polyclonal Antibodies Research: 1 fractional worksImmune Cell Function and Interaction: 1 fractional worksImmunotherapy and Immune Responses: 1 fractional worksT-cell and B-cell Immuno…1T-cell and B-cell Immunology: 1 fractional worksvaccines and immunoinformatics approaches: 0 fractional worksCancer Immunotherapy and Biomarkers: 0 fractional worksBiosimilars and Bioanalytical Methods: 0 fractional worksLymphoma Diagnosis and Treatment: 0 fractional worksClick Chemistry and Applications: 0 fractional works
OncologyRadiology, Nuclear Medicine and ImagingImmunologyMolecular Biology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 CAR-T cell therapy research Oncology 4 works
  2. 2 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  3. 3 Immune Cell Function and Interaction Immunology 1 works
  4. 4 Immunotherapy and Immune Responses Immunology 1 works
  5. 5 T-cell and B-cell Immunology Immunology 1 works
  6. 6 vaccines and immunoinformatics approaches Molecular Biology 0 works
  7. 7 Cancer Immunotherapy and Biomarkers Oncology 0 works
  8. 8 Biosimilars and Bioanalytical Methods Immunology 0 works
  9. 9 Lymphoma Diagnosis and Treatment Pathology and Forensic Medicine 0 works
  10. 10 Click Chemistry and Applications Organic Chemistry 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available51.2%not open48.8%

World: 40% of research is openly available.

with international co-authors39.6%domestic only60.4%

World: 18% is written across borders.

How has Immatics Biotechnologies (Germany)'s research output changed?

Output in 2022-2025 was 1% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Immatics Biotechnologies (Germany) as a percentage of every work published that year, 0.000089% in 2024.

still counting0.00010%0.00020%Immatics Biotechnologies (Germany)0.000043% in 20251990200020102020

Fractional works of Immatics Biotechnologies (Germany) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Tübingen

All research institutions in Tübingen

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Immatics Biotechnologies (Germany). Posts are plain text and can be reported.